NCT00445588View on ClinicalTrials.gov

Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Adult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain Tumor
Interventions
DRUG

erlotinib hydrochloride

150mg Given orally once daily

DRUG

sorafenib tosylate

400mg Given orally twice daily

OTHER

pharmacological study

Correlative studies

Trial Locations (9)

19104

University of Pennsylvania, Philadelphia

21287

Johns Hopkins University, Baltimore

27157

Wake Forest University Health Sciences, Winston-Salem

30322

Emory University, Atlanta

33612

Moffitt Cancer Center, Tampa

35294

University of Alabama at Birmingham, Birmingham

44195

Cleveland Clinic, Cleveland

48202

Henry Ford Hospital, Detroit

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00445588 - Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter